{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:37Z","timestamp":1784998957798,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10147-026-03085-0","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:18:00Z","timestamp":1781270280000},"page":"1710-1720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CHD6 promotes triple-negative breast cancer progression and is associated with PI3K\/AKT and MAPK pathways"],"prefix":"10.1007","volume":"31","author":[{"given":"Bokan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"1","key":"3085_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL et al (2025) Cancer statistics 2025. CA A Cancer J Clin 75(1):10\u201345","journal-title":"CA A Cancer J Clin"},{"issue":"1","key":"3085_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL et al (2023) Cancer statistics 2023. CA A Cancer J Clin 73(1):17\u201348","journal-title":"CA A Cancer J Clin"},{"issue":"7","key":"3085_CR3","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1172\/JCI44745","volume":"121","author":"LLC Marotta","year":"2011","unstructured":"Marotta LLC et al (2011) The JAK2\/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J Clin Investig 121(7):2723\u20132735","journal-title":"J Clin Investig"},{"issue":"2","key":"3085_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176\u2013198","journal-title":"Cancer Discov"},{"issue":"2","key":"3085_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G et al (2022) Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat Rev Clin Oncol 19(2):91\u2013113","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"3085_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u20131948","journal-title":"N Engl J Med"},{"issue":"1","key":"3085_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/srep00227","volume":"2","author":"RM Hallett","year":"2012","unstructured":"Hallett RM et al (2012) A gene signature for predicting outcome in patients with basal-like breast cancer. Sci Rep 2(1):227","journal-title":"Sci Rep"},{"key":"3085_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y et al (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15:121","journal-title":"J Hematol Oncol"},{"issue":"10","key":"3085_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12032-024-02456-9","volume":"41","author":"Y Hu","year":"2024","unstructured":"Hu Y et al (2024) The treatment landscape of triple-negative breast cancer. Med Oncol 41(10):236","journal-title":"Med Oncol"},{"key":"3085_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","volume":"497","author":"X Bai","year":"2021","unstructured":"Bai X et al (2021) Triple-negative breast cancer therapeutic resistance: where is the Achilles\u2019 heel? Cancer Lett 497:100\u2013111","journal-title":"Cancer Lett"},{"key":"3085_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO (2023) Triple negative breast cancer treatment options and limitations: Future outlook. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15071796","journal-title":"Pharmaceutics"},{"key":"3085_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","volume":"78","author":"CR Clapier","year":"2009","unstructured":"Clapier CR, Cairns BR (2009) The biology of chromatin remodeling complexes. Annu Rev Biochem 78:273\u2013304","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"3085_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1172\/JCI123557","volume":"129","author":"Y Ding","year":"2019","unstructured":"Ding Y et al (2019) Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest 129(2):759\u2013773","journal-title":"J Clin Invest"},{"key":"3085_CR14","doi-asserted-by":"crossref","unstructured":"Bg, W. and R. Cw, SWI\/SNF nucleosome remodellers and cancer. Nature reviews. Cancer, 2011. 11(7).","DOI":"10.1038\/nrc3068"},{"key":"3085_CR15","doi-asserted-by":"crossref","unstructured":"Dc, H. and C. Gr, ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res 2011. 21(3).","DOI":"10.1038\/cr.2011.32"},{"issue":"4","key":"3085_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026450","volume":"7","author":"AA Mills","year":"2017","unstructured":"Mills AA (2017) The chromodomain helicase DNA-binding chromatin remodelers: family traits that protect from and promote cancer. Cold Spring Harb Perspect Med 7(4):a026450","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"3085_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1139\/O07-063","volume":"85","author":"JA Hall","year":"2007","unstructured":"Hall JA, Georgel PT (2007) CHD proteins: a diverse family with strong ties. Biochem Cell Biol 85(4):463\u2013476","journal-title":"Biochem Cell Biol"},{"issue":"1","key":"3085_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41467-018-08111-y","volume":"10","author":"S Moore","year":"2019","unstructured":"Moore S et al (2019) The CHD6 chromatin remodeler is an oxidative DNA damage response factor. Nat Commun 10(1):241","journal-title":"Nat Commun"},{"issue":"7280","key":"3085_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature08911","volume":"463","author":"L Ho","year":"2010","unstructured":"Ho L, Crabtree GR (2010) Chromatin remodelling during development. Nature 463(7280):474\u2013484","journal-title":"Nature"},{"issue":"9","key":"3085_CR20","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/2159-8290.CD-19-1352","volume":"10","author":"D Zhao","year":"2020","unstructured":"Zhao D et al (2020) Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer. Cancer Discov 10(9):1374\u20131387","journal-title":"Cancer Discov"},{"issue":"18","key":"3085_CR21","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1158\/0008-5472.CAN-20-1049","volume":"80","author":"Y Wang","year":"2020","unstructured":"Wang Y et al (2020) CHD4 promotes breast cancer progression as a coactivator of hypoxia-inducible factors. Cancer Res 80(18):3880\u20133891","journal-title":"Cancer Res"},{"issue":"5","key":"3085_CR22","first-page":"903","volume":"8","author":"Y Li","year":"2018","unstructured":"Li Y et al (2018) CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling. Am J Cancer Res 8(5):903\u2013914","journal-title":"Am J Cancer Res"},{"issue":"5","key":"3085_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2017.04.005","volume":"31","author":"L Xia","year":"2017","unstructured":"Xia L et al (2017) CHD4 has oncogenic functions in initiating and maintaining epigenetic suppression of multiple tumor suppressor genes. Cancer Cell 31(5):653-668.e7","journal-title":"Cancer Cell"},{"issue":"4","key":"3085_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","volume":"37","author":"Z Zhang","year":"2020","unstructured":"Zhang Z et al (2020) Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation. Cancer Cell 37(4):584-598.e11","journal-title":"Cancer Cell"},{"issue":"3","key":"3085_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/0008-5472.CAN-13-3056","volume":"74","author":"V Kolla","year":"2014","unstructured":"Kolla V et al (2014) Role of CHD5 in human cancers: 10 years later. Can Res 74(3):652\u2013658","journal-title":"Can Res"},{"issue":"5","key":"3085_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41388-021-02081-0","volume":"41","author":"AK Laut","year":"2021","unstructured":"Laut AK et al (2021) CHD5 inhibits metastasis of neuroblastoma. Oncogene 41(5):622","journal-title":"Oncogene"},{"issue":"10","key":"3085_CR27","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1093\/hmg\/ddv032","volume":"24","author":"A Sancho","year":"2015","unstructured":"Sancho A et al (2015) CHD6 regulates the topological arrangement of the CFTR locus. Hum Mol Genet 24(10):2724\u20132732","journal-title":"Hum Mol Genet"},{"issue":"1-2","key":"3085_CR28","first-page":"31","volume":"750","author":"FKT Stanley","year":"2013","unstructured":"Stanley FKT, Moore S, Goodarzi AA (2013) CHD chromatin remodelling enzymes and the DNA damage response. Mutat Res 750(1\u20132):31\u201344","journal-title":"Mutat Res"},{"key":"3085_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41421-022-00478-z","volume":"8","author":"B Zhang","year":"2022","unstructured":"Zhang B et al (2022) The chromatin remodeler CHD6 promotes colorectal cancer development by regulating TMEM65-mediated mitochondrial dynamics via EGF and Wnt signaling. Cell Discov 8:130","journal-title":"Cell Discov"},{"issue":"21","key":"3085_CR30","doi-asserted-by":"publisher","first-page":"12186","DOI":"10.1093\/nar\/gkac1090","volume":"50","author":"D Zhao","year":"2022","unstructured":"Zhao D et al (2022) CHD6 promotes broad nucleosome eviction for transcriptional activation in prostate cancer cells. Nucleic Acids Res 50(21):12186\u201312201","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"3085_CR31","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/0008-5472.CAN-24-0787","volume":"85","author":"J Jin","year":"2025","unstructured":"Jin J et al (2025) Chromatin helicase CHD6 establishes proinflammatory enhancers and is a synthetic lethal target in FH-deficient renal cell carcinoma. Cancer Res 85(4):675\u2013691","journal-title":"Cancer Res"},{"issue":"37","key":"3085_CR32","doi-asserted-by":"publisher","first-page":"60712","DOI":"10.18632\/oncotarget.10858","volume":"7","author":"D Massihnia","year":"2016","unstructured":"Massihnia D et al (2016) Triple negative breast cancer: shedding light onto the role of PI3K\/AKT\/mTOR pathway. Oncotarget 7(37):60712\u201360722","journal-title":"Oncotarget"},{"issue":"8","key":"3085_CR33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","volume":"30","author":"F Janku","year":"2012","unstructured":"Janku F et al (2012) PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777\u2013782","journal-title":"J Clin Oncol"},{"issue":"7418","key":"3085_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Network, C.G.A.","year":"2012","unstructured":"Network, C.G.A. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370","journal-title":"Nature"},{"issue":"4","key":"3085_CR35","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1007\/s13277-016-4856-x","volume":"37","author":"D Massihnia","year":"2016","unstructured":"Massihnia D et al (2016) A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumour Biol 37(4):4263\u20134273","journal-title":"Tumour Biol"},{"issue":"5853","key":"3085_CR36","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1126\/science.1145720","volume":"318","author":"LD Wood","year":"2007","unstructured":"Wood LD et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318(5853):1108\u20131113","journal-title":"Science"},{"issue":"20","key":"3085_CR37","doi-asserted-by":"publisher","first-page":"29321","DOI":"10.18632\/oncotarget.8722","volume":"7","author":"D Fanale","year":"2016","unstructured":"Fanale D et al (2016) Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? Oncotarget 7(20):29321\u201329332","journal-title":"Oncotarget"},{"issue":"4","key":"3085_CR38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ctrv.2012.11.002","volume":"39","author":"AM Gonzalez-Angulo","year":"2013","unstructured":"Gonzalez-Angulo AM, Blumenschein GR (2013) Defining biomarkers to predict sensitivity to PI3K\/Akt\/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39(4):313\u2013320","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"3085_CR39","first-page":"1997","volume":"19","author":"Y-J Guo","year":"2020","unstructured":"Guo Y-J et al (2020) ERK\/MAPK signalling pathway and tumorigenesis. Exp Ther Med 19(3):1997\u20132007","journal-title":"Exp Ther Med"},{"key":"3085_CR40","doi-asserted-by":"publisher","DOI":"10.7150\/jca.44727","author":"Z Dl","year":"2020","unstructured":"Dl Z et al (2020) Fibroblast growth factor receptor signaling as therapeutic targets in female reproductive system cancers. J Cancer. https:\/\/doi.org\/10.7150\/jca.44727","journal-title":"J Cancer"},{"issue":"5","key":"3085_CR41","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook MA et al (2021) Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer 124(5):880\u2013892","journal-title":"Br J Cancer"},{"issue":"1","key":"3085_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y et al (2020) FGF\/FGFR signaling in health and disease. Signal Transduct Target Ther 5(1):181","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"3085_CR43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D et al (2019) Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol 37(8):907\u2013915","journal-title":"Nat Biotechnol"},{"issue":"3","key":"3085_CR44","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea M et al (2015) StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol 33(3):290\u2013295","journal-title":"Nat Biotechnol"},{"issue":"7","key":"3085_CR45","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30(7):923\u2013930","journal-title":"Bioinformatics"},{"issue":"12","key":"3085_CR46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550","journal-title":"Genome Biol"},{"issue":"1","key":"3085_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1):139\u2013140","journal-title":"Bioinformatics"},{"issue":"5","key":"3085_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G et al (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. Omics A J Integr Biol 16(5):284\u2013287","journal-title":"Omics A J Integr Biol"},{"issue":"43","key":"3085_CR49","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43):15545\u201315550","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3085_CR50","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12672-024-01173-z","volume":"15","author":"DE Bogale","year":"2024","unstructured":"Bogale DE (2024) The roles of FGFR3 and c-MYC in urothelial bladder cancer. Discov Oncol 15(1):295","journal-title":"Discov Oncol"},{"issue":"7","key":"3085_CR51","doi-asserted-by":"publisher","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","volume":"20","author":"S Du","year":"2023","unstructured":"Du S, Zhang Y, Xu J (2023) Current progress in cancer treatment by targeting FGFR signaling. Cancer Biol Med 20(7):490\u2013499","journal-title":"Cancer Biol Med"},{"issue":"24","key":"3085_CR52","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-23-1065","volume":"83","author":"Y Ouyang","year":"2023","unstructured":"Ouyang Y et al (2023) FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress t-cell recruitment and activation. Cancer Res 83(24):4030\u20134046","journal-title":"Cancer Res"},{"issue":"3","key":"3085_CR53","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/bcr3182","volume":"14","author":"X Wu","year":"2012","unstructured":"Wu X et al (2012) Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res 14(3):R73","journal-title":"Breast Cancer Res"},{"issue":"4","key":"3085_CR54","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T et al (2019) Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest 129(4):1785\u20131800","journal-title":"J Clin Invest"},{"issue":"1","key":"3085_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13058-024-01844-3","volume":"26","author":"Y Lu","year":"2024","unstructured":"Lu Y et al (2024) Evaluating the immunologically \u201ccold\u201d tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models. Breast Cancer Res 26(1):104","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3085_CR56","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/s41467-025-56085-5","volume":"16","author":"L Provencher","year":"2025","unstructured":"Provencher L et al (2025) CHD6 has poly(ADP-ribose)- and DNA-binding domains and regulates PARP1\/2-trapping inhibitor sensitivity via abasic site repair. Nat Commun 16(1):1026","journal-title":"Nat Commun"},{"issue":"1","key":"3085_CR57","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1038\/s41467-021-23327-1","volume":"12","author":"Y Kargapolova","year":"2021","unstructured":"Kargapolova Y et al (2021) Overarching control of autophagy and DNA damage response by CHD6 revealed by modeling a rare human pathology. Nat Commun 12(1):3014","journal-title":"Nat Commun"},{"issue":"21","key":"3085_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112815","volume":"23","author":"F-L Zhang","year":"2022","unstructured":"Zhang F-L, Li D-Q (2022) Targeting chromatin-remodeling factors in cancer cells: promising molecules in cancer therapy. Int J Mol Sci 23(21):12815","journal-title":"Int J Mol Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03085-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:45Z","timestamp":1784997345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03085-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3085"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03085-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal studies were approved by the Animal Experimental Ethical Inspection of the First Affiliated Hospital, Zhejiang University School of Medicine, under institutional approval number 2026045. The studies involving humans were approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee\/institutional review board waived the requirement of written informed consent for participation from the participants or the participants\u2019 legal guardians\/next of kin because this study was retrospective in nature and all analyzed data were anonymized.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}